Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Development of RApid Point-of-Care test Platforms for Infectious Diseases (RAPP-ID)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Innovative Medicines Initiative
Action type: Collaborative project
Partnership: IMI (Art-185)
Countries involved: Belgium,Belgium,Sweden,United Kingdom,Germany,Belgium,Belgium,Germany,Netherlands,United Kingdom,Switzerland,Sweden,United Kingdom,Italy,France,United States,Finland
Call:  (IMI-JU-02-2009, 2009)
Start date: 2011-04-01
End date: 2016-09-30
Duration (months): 66.0
Total project cost (EUR): 15927300.0
EU funding (EUR): 6828438.0
Participants: 20
Project status: CLOSED

RAPP-ID (“Development of RApid Point-of-Care test Platforms for Infectious Diseases”) will develop a Point-of-Care Test (POCT) for rapid (hospital <2h, primary care <30min) detection of bacteria, mycobacteria, fungi, as well as viruses and host biomarkers by combining novel specific probes, novel methods of sample preparation, and demonstrated ultra-high sensitive detection methods. The platforms will also determine resistance to antimicrobial drugs. The research will focus on the biomarkers and pathogens involved in 1) Sepsis, 2) Lower Respiratory Tract Infections (LRTI), including Community-Acquired Pneumonia (CAP) and Ventilator-Associated Pneumonia (VAP), and 3) Tuberculosis (TB). Detection of bacteria, fungi and antibiotic resistance will mainly involve Nucleic Acid (NA) tests, whereas viral and host biomarker detection will mainly involve selective immunobinding with a probe or with a sensor surface. The diagnostic tests consist of in four functional modules: 1) sample collection and interfacing, 2) upconcentration and extraction, 3) signal and/or sample amplification, and 4) detection. RAPP-ID will integrate the minimum number of modules required for each disease/syndrome in a microfluidic cartridge, for which a breadboard reader with Graphical User Interface (GUI) provides the necessary optical/fluidic/electric/thermal interfaces. The integrated POCT will be validated on (spiked) reference samples and well characterised clinical samples and compared with the best reference standards and other standard available diagnostic tests.

Keywords: poct infectious diseases
Anti-Biopharmaceutical Immunization:Prediction and analysis of clinical relevance to minimize the risk (ABIRISK)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Innovative Medicines Initiative
Action type: Collaborative project
Partnership: IMI (Art-185)
Countries involved: United Kingdom,France,Italy,Switzerland,Netherlands,Netherlands,Italy,Israel,Germany,Germany,Germany,Sweden,Austria,Germany,Denmark,Spain,Germany,Germany,Czechia,Belgium,France,Germany,Denmark,Germany,Denmark,Sweden
Call:  (IMI-JU-03-2010, 2010)
Start date: 2012-03-01
End date: 2018-02-28
Duration (months): 72.0
Total project cost (EUR): 32851056.0
EU funding (EUR): 18170217.0
Participants: 38
Project status: CLOSED

The ABIRISK project provides an integrated approach to the study of immunization against biopharmaceuticals, bringing together a unique panel of experts from different disciplines. ABIRISK will involve many of the European leaders in rheumatology, gastroenterology, hemophilia and multiple sclerosis, caring for ~30,000 patients treated with biopharmaceuticals, with ~10,000 additional patients recruited per year. This should lead to the constitution of the largest possible cohort in Europe for the study of immunogenicity, a condition critical for the success of the program. ABIRISK will also benefit from the unique expertise of immunologist partners in the development of innovative strategies for predicting the immunogenicity of biopharmaceuticals and for defining its mechanisms. The large number of patients enrolled in the ABIRISK cohorts should make it possible to study the genetic basis of immunogenicity in a new way. We will standardize all clinical and biological information before its integration into a large database for evaluation of the clinical relevance of immunization against biopharmaceuticals and stratification of the risk to patients as a function of factors linked to treatment or to the individual. Computational biology and biostatistical modeling will be used to develop models for predicting immunogenicity that will be validated with the ABIRISK database. The complementarity between the clinical partners from different disciplines, immunologists, methodologists and biostatisticians will create a unique task force for studies of biopharmaceutical immunogenicity. The direct outcomes of the proposed work will be greater understanding of the mechanisms involved in the emergence of anti-drug antibodies, the development of new methods for predicting immunogenicity and a comprehensive view of the respective value of predictive tools, and guidelines for the development of new biopharmaceuticals and patient care.
Kinetics for Drug Discovery (K4DD) (K4DD)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Innovative Medicines Initiative
Action type: Collaborative project
Partnership: IMI (Art-185)
Countries involved: Germany,Netherlands,Netherlands,United Kingdom,Germany,United Kingdom,United Kingdom,United Kingdom,United Kingdom,Germany,Germany,Sweden,Belgium,Germany,Switzerland,Germany,Austria,Germany
Call:  (IMI-JU-04-2011, 2011)
Start date: 2012-11-01
End date: 2017-10-31
Duration (months): 60.0
Total project cost (EUR): 20860250.0
EU funding (EUR): 8286930.0
Participants: 21
Project status: CLOSED

There is mounting evidence that the often ignored kinetic aspects of the interaction between a drug and its target are highly relevant for clinical success. This ignorance may be one of the reasons for the high attrition rates in drug discovery, as it has been analyzed that many recently marketed drugs had indeed improved kinetic profiles. This hindsight knowledge needs to be converted into data-driven guidelines and easily accessible high-throughput assays for future drug discovery and fuels the K4DD consortium of over 20 partners, EFPIA members, universities, research institutes and SMEs. Our integrated approach will lead to the definition of any compound in terms of its target ‘kinotype’, next to affinity and selectivity. For us, integration means analyzing the kinetic behavior of different targets (GPCRs, kinases, proteases) across the three work packages. The partners in the consortium are European key players: they elucidate(d) structures of GPCRs and kinases, are at the forefront of bioanalytical techniques, e.g. surface plasmon resonance, are world-leaders in PKPD modeling, and bring the best of computational resources for e.g. molecular dynamics calculations. Thus, we study the drug-target interaction from picoseconds to >hours, for both soluble and membrane-bound proteins. At the end of the consortium’s lifetime we anticipate that kinetic aspects of the drug-target interaction can routinely be studied in robust and accessible assays within and outside the consortium, that editors and reviewers routinely ask for a compound’s kinetic data next to its affinity and selectivity, that ‘kinotypic’ knowledge helps define the target product profile and guide the subsequent lead finding and optimization process, and that kinetic guidelines for predictive PKPD modeling approaches are the logical consequence of our efforts. Thus, the overall ambition of the consortium is to instill lasting kinetic awareness into the pharma community.

Keywords: kinetics,drug,drug target,gpcr,kinase,protease,in vivo translation,attrition
Molecular basis of the outer membrane permeability (TRANSLOCATION)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Innovative Medicines Initiative
Action type: Collaborative project
Partnership: IMI (Art-185)
Countries involved: United Kingdom,Germany,Italy,United Kingdom,Germany,Ireland,Germany,United Kingdom,Germany,Switzerland,Germany,France,France,France,Sweden,Belgium,Spain,Germany,Germany,Netherlands,Denmark
Call:  (IMI-JU-06-2012, 2012)
Start date: 2013-01-01
End date: 2018-06-30
Duration (months): 66.0
Total project cost (EUR): 29754154.0
EU funding (EUR): 15984203.0
Participants: 28
Project status: CLOSED

Overcoming the barriers that the cell envelope and efflux pumps provide to Gram-negative bacteria is a major bottleneck in the discovery and development of new antibiotics. To respond to this Call we are extending our current network on antibiotic translocation and propose an ambitious project ranging from identification of novel resistance mechanisms in clinical bacterial isolates to crystallization of molecular resistance components and all-atom modeling to determine the kinetics of permeation. Our particular strength lies in the identification and quantification of transport proteins involved in membrane permeation at the cellular level combined with our expertise in quantifying the rate limiting steps of translocation at atomic level. Based on our experience we intend to: 1. develop multiple assays to determine intracellular concentrations of small molecules 2. increase the overall structural knowledge of outer membrane proteins 3. extend knowledge on active-uptake transport systems, such as iron transport 4. identify novel targets whose modulation can alter the penetration of other small molecules 5. obtain as complete a picture as possible of small molecule penetration into and efflux out of bacterial cells Combining the research question at different levels we expect to understand the complexity of membrane permeability. In particular, we are convinced that our molecular approach is able to provide a general template for a guided design of antibiotics to achieve high permeability. In addition, we will create a data base to allow the sharing of antibacterial R&D information on an unprecedented level. Also, via careful analysis of this information we intend to provide learnings as best practices that will lead to an increase in the overall efficiency of antibacterial R&D.

Keywords: bacteria,antibiotic,penetration,porin,efflux,transport,gram-negative,knowledge dissemination
MOdeling and DEsign of Reliable, process variation-aware Nanoelectronic devices, circuits and systems (MODERN)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Electronic Numerical Integrator and Computer
Action type: Collaborative project
Partnership: ENIAC (Art-185)
Countries involved: France,Netherlands,Italy,France,Italy,Greece,Austria,Austria,Spain,Germany,Italy,Switzerland,France,United Kingdom,Austria,Netherlands,Denmark
Call:  (JU-ENIAC-2008-1, 2008)
Start date: 2009-03-01
End date: 2012-02-01
Duration (months): 35.0
Total project cost (EUR): 27363006.0
EU funding (EUR): 4385254.0
Participants: 29
Project status: CLOSED

The influence of process variations is becoming extremely critical for nanoCMOS technology nodes, due to geometric tolerances and manufacturing non-idealities (such as edge or surface roughness, or the fluctuation of the number of doping atoms). As a result, production yields and figures of merit of a circuit such as performance, power, and reliability have become extremely sensitive to uncontrollable statistical process variations. Although some kind of variability has always existed and been taken into account for designing integrated circuits, the largest impact of variability and the greater influence of random or spatial aspects are setting up a completely new challenge. On top of those difficulties, the deficiency of design techniques and EDA methodologies for tackling PVs makes that challenge even more critical. The objective of the MODERN project is to develop new paradigms in integrated circuit design which will enable the manufacturing of reliable, low cost, low EMI, high-yield complex products using unreliable and variable devices. Specifically, the main goals of the project are: 1. Advanced, yet accurate, models of process variations for nanometer devices, circuits and complex architectures. 2. Effective methods for evaluating the impact of process variations on manufacturability, design reliability and circuit performances. - Reliability, noise, EMC/EMI. - Timing, power and yield. 3. Design methods and tools to mitigate or tolerate the effects of process variations on those quantities applicable at the device, circuit and architectural levels. 4. Validation of the modeling and design methods and tools on a variety of silicon demonstrators. The MODERN Consortium features strong competence and expertise in the field of advanced technologies, with a well-balanced participation between industry and research institutes.

Keywords: variability reliability nanoelectronic devices circuit system modeling electromagnetic-compatibility
Implementing Manufacturing science solutions to increase equipment PrOductiVity and fab pErformance (IMPROVE)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Electronic Numerical Integrator and Computer
Action type: Collaborative project
Partnership: ENIAC (Art-185)
Countries involved: France,France,Italy,Germany,Austria,Austria,France,France,Germany,Italy,France,Portugal,Austria,Italy,Ireland,Germany,Germany,Germany,Germany,Germany,Germany
Call:  (JU-ENIAC-2008-1, 2008)
Start date: 2009-03-01
End date: 2012-02-01
Duration (months): 35.0
Total project cost (EUR): 37612640.0
EU funding (EUR): 6281312.0
Participants: 36
Project status: CLOSED

IMPROVE aims to improve European Semiconductor fabs efficiency by providing methods and tools to better control the process variability, reduce the cycle time and enhance the effectiveness of the production equipment. This will be achieved thanks to 3 major developments. The development of Virtual Metrology technics allowing to control the process at wafer level whilst suppressing standard metrology steps. The development of Predictive Equipment Behaviour technics to improve the process tools reliability whilst optimizing the maintenance frequency and increasing the equipment uptime. The development of Dynamic Risk Assessment and Dynamic Control Plan concepts, suppressing unnecessary measurements steps whilst dynamiccaly improving the control plan efficiency . The impact of the integration of these technics in the line decision systems will also be evaluated and assessed. .

Keywords: process control,metrology,equipment,apc
Large area silicon carbide substrates and heteroepitaxial GaN for power device applications (LAST POWER)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Electronic Numerical Integrator and Computer
Action type: Collaborative project
Partnership: ENIAC (Art-185)
Countries involved: Italy,Greece,France,Spain,Italy,Poland,Italy,Sweden,Greece,Germany,Sweden
Call:  (ENIAC-2009-1, 2009)
Start date: 2010-04-01
End date: 2013-10-01
Duration (months): 42.0
Total project cost (EUR): 16285285.0
EU funding (EUR): 2719643.0
Participants: 15
Project status: CLOSED

Power microelectronics represents an important segment of the semiconductor industry worldwide and is generally characterised by devices with low revenue but high strategic importance. The aim of the ENIAC JU project LAST POWER project is to make the European Union independent from other sources in the design and production of highly-efficient systems for applications controlling electrical power. The project focuses on the development of high-power technologies and devices for both the forthcoming era of pure electrical mobility and a variety of industries which make use of electrical drivers.
European 450mm Equipment & Materials Initiative (EEMI 450)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Electronic Numerical Integrator and Computer
Action type: Collaborative project
Partnership: ENIAC (Art-185)
Countries involved: Germany,Germany,France,Belgium,United Kingdom,Netherlands,France,Austria,Germany,Hungary,Germany,Netherlands,France,France,Netherlands,Germany,Netherlands,Ireland,Germany,Germany,Germany,Germany
Call:  (ENIAC-2009-1, 2009)
Start date: 2010-04-01
End date: 2013-03-01
Duration (months): 35.0
Total project cost (EUR): 18324650.0
EU funding (EUR): 2996901.0
Participants: 27
Project status: CLOSED

Large-scale semiconductor fabrication is now standardised on 300mm diameter wafers. However, as demand grows and node dimensions diminish, major chipmakers are considering offsetting the growing costs of miniaturisation by increasing wafer size to 450mm to cut cost per produced die. A prerequisite is the availability of the required quality wafers and equipment able to handle larger wafers. The ENIAC JU project EEMI450 brings together the major European specialists to start such work to maintain and extend their leading role in the development and production of semiconductor equipment and materials.
Efficient Silicon Multi-Chip System-in-Package Integration - Reliability, Failure Analysis and Test (ESIP)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Electronic Numerical Integrator and Computer
Action type: Collaborative project
Partnership: ENIAC (Art-185)
Countries involved: Germany,Italy,Netherlands,Netherlands,Belgium,France,France,France,Germany,Finland,Norway,Austria,France,Austria,Germany,France,United Kingdom,Austria,Netherlands,Germany,United Kingdom,Belgium,Italy,Germany,Italy,Germany
Call:  (ENIAC-2009-1, 2009)
Start date: 2010-05-01
End date: 2013-04-01
Duration (months): 35.0
Total project cost (EUR): 36514419.0
EU funding (EUR): 5816319.0
Participants: 41
Project status: CLOSED

The ENIAC JU project ESiP is addressing the issues of reliability, failure analysis and testing in innovative system-in-package (SiP) solutions. Highly integrated systems with greater miniaturisation and increased functionality open new markets and improve the quality of life through a wide range of applications. In particular, higher systems integration technologies using multi-chip packaging, through-silicon via technologies or package-stacking approaches are growing in importance. Market studies show that SiP devices will have an average growth of 10 to 20% per year over the next five years.
The Researchers' Night 2007 in Norway (RESEARCH-NIGHT-NOR)

Framework: FP7 — People
Programme: Marie-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: European Researchers' Night
Action type: Coordination and support actions
Countries involved: Norway
Call:  (FP7-PEOPLE-2007-5-1-1-NIGHT, 2007)
Start date: 2007-05-01
End date: 2007-11-30
Duration (months): 7.0
Total project cost (EUR): 150375.0
EU funding (EUR): 100000.0
Participants: 1
Project status: CLOSED

“Researchers’ Night 2007 in Norway” (RN) is planned as a nation-wide promotion effort in line with the objectives of the EU FP7 “People” Work Programme and the call FP7-PEOPLE 2007-5-1-1-NIGHT, organised as add-on to the “Forskningsdagene” Science Week, 21-300907 comprising 1000 events by 200 local organisers all over Norway, coordinated by the Research Council of Norway (RCN). This coordinated proposal from Norway includes 14 proposed local events selected after national competition and substantial co-financing. The project aims to bring the public at large (kids, teenagers, adults, parents, teachers, entrepreneurs, politicians - and media - in close contact and dialogue with researchers under informal, pleasant, enjoyable, attractive and innovative circumstances. We will promote the contribution of research and researchers to the society at large, bring the researchers closer to the large public, involve researchers who have benefited from EU support, seek to “de-mystify” research, demonstrate the fascination of research, show researchers’ passion for research and allow direct involvement of the public with the researchers in ”hands-on” experiments, science cafés, science quiz, ”real science” etc. A drawing competition “draw a researcher” will be organised in line with the call and the previous success by the RCN “Nysgjerrig-Per” drawing competition for pupils web-published in “Nature”. An EC stand will be prepared according to the call. Industrial partners are engaged in several of the subcontracted events. All local and national initiatives will be demanded to be widely announced in the media. The RCN will prepare and disseminate national information material, including newspaper inlets in nation-wide newspapers (325.000 copies), advertisements, brochures, emails, and web-site information on www.rcn.no, www.forskning.no, www.forskningsdagene.no , www.nysgjerriper.no and www.eracareers.no. An evaluation of the project will be carried out at end of project.

Keywords: researchers night public communication events
Israel Night of Science (ISRANOS)

Framework: FP7 — People
Programme: Marie-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: European Researchers' Night
Action type: Coordination and support actions
Countries involved: Israel
Call:  (FP7-PEOPLE-2007-5-1-1-NIGHT, 2007)
Start date: 2007-07-01
End date: 2008-01-31
Duration (months): 7.0
Total project cost (EUR): 233702.0
EU funding (EUR): 140000.0
Participants: 10
Project status: CLOSED

Whoever studies science and does not use it for the benefit of others is like a farmer who ploughs a field without sowing it. (Tolstoy) The proposed project intends to provide an opportunity for lively, informal interchange, between scientists/researchers and the general public of all ages in Israel. We wish to present, through a diverse range of activities, opportunities for researchers and scientists to engage in a meaningful dialogue with the general public so that we can begin to demythologize the perceived image of scientist/researcher as inaccessible, remote and aloof. By changing this image we can erode public mistrust of science and the unwillingness of young people to purse a career in research. Employing imaginative and vibrant interactive activities we will further enhance and strengthen the rich cultural heritage of science in Israel and the European Union; promote science literacy among Israelis of all ages; and encourage youngsters to pursue science studies towards a career in science and technology.

Keywords: researchers,science,youth